Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502433 | 1.00 | LMNA (0.55) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL362445 | 0.91 | LMNA (0.55) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL3471214 | 0.90 | LMNA (0.56) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL3711173 | 0.90 | LMNA (0.56) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL2926517 | 0.90 | HTR4 (0.56) | CYP2D6HTR1AHTR4ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL2925147 | 0.88 | HTR4 (0.57) | CYP2D6HTR1AHTR4ALDH1A1MEN1 | |
| SCHEMBL6442660 | 0.87 | LMNA (0.51) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL3534600 | 0.87 | LMNA (0.51) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL5499989 | 0.84 | KDM4E (0.57) | LMNAKDM4ETDP1KEAP1NFE2L2 | |
| SCHEMBL6532154 | 0.84 | KDM4E (0.57) | LMNAKDM4ETDP1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705145-B2 | Process for the preparation of 4-(3′-chloro-4′-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2010-04-27 | — | — | US | claimed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | claimed |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | claimed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | claimed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | claimed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | disclosed |
| CN-110747489-B | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2021-05-07 | — | — | CN | disclosed |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2020-10-22 | — | — | US | disclosed |
| CN-110747489-A | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2020-02-04 | — | — | CN | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-7705145-B2 | Process for the preparation of 4-(3′-chloro-4′-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
| WO-2005070909-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GEFITINIB | NATCO PHARMA LIMITED (IN) | 2005-08-04 | — | — | WO | disclosed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-20050037445-A1 | Oncology drug innovation | POULSEN, HANS SKOVGAARD (DK) | 2005-02-17 | — | — | US | disclosed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | MAP7, NQO2, ABL1 | LMNA 732/4885KDM4E 756/4885TDP1 3649/4885 |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | CYP3A7, CYP3A5, CYP4B1 | LMNA 2749/4885KDM4E 339/4885TDP1 2438/4885 |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | PAH, NQO2, MAP7 | LMNA 750/4885KDM4E 591/4885TDP1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.